Kelly W Padilla

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

M. Pangalos, Yuan Yuan, K. Psachoulia, 2022, The New England journal of medicine.

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

M. Pangalos, Yuan Yuan, K. Psachoulia, 2021, Open Forum Infectious Diseases.

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

H. Jessen, M. Pangalos, R. Fischer, 2022, The Lancet Respiratory Medicine.